louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02360410: Check Yourself Study
Official title: Promoting Adolescent Health Through Personalized Feedback
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Health Risk Behaviors
Health Care Services Quality of Care
Lead sponsor: Seattle Children's Hospital
Sponsor class: OTHER
First posted: 2015-02-10
Enrollment: 300
Sex: ALL
Minimum age (years): 13
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The proposed study is a randomized controlled trial that compares the effectiveness of an electronic personalized health screening app incorporating motivational feedback (i.e., "Check Yourself") to usual care. The purpose of this study is to determine whether Check Yourself is more effective than usual care in reducing health risk behaviors and improving quality of care among adolescents receiving primary health care services.


Eligibility criteria: Inclusion Criteria:

* Eligible individuals will be 13-18 years old who have an appointment to see a provider at a participating clinic and will be able to read and comprehend English.

Exclusion Criteria:

* Individuals will be excluded from the study if:

  * they do not meet age requirements,
  * do not have an appointment at a participating clinic,
  * lack the means to complete follow-up interviews (i.e., has neither telephone not internet access),
  * have a sibling who has/is being enrolled in the study and/or
  * are not able to read or comprehend English.

Primary outcomes:
measure: Number of Health risk behaviors
timeFrame: 3 months
measure: Number of risk behaviors counseled on during primary care appointment
timeFrame: 1 day
Secondary outcomes:
measure: Adolescent Satisfaction with Care
timeFrame: 1 day
measure: Interval Receipt of Care
timeFrame: 3 months
measure: Motivation for Health Behavior Change
timeFrame: 1 day
measure: Specific Health Risk Behavior Change
timeFrame: 3 months
Other outcomes:
measure: Adolescent Perceived Support from their Primary Care Provider
timeFrame: 1 day
measure: Adolescent Health Self-Efficacy
timeFrame: 1 day
Locations:
city: Seattle
country: United States
facility: Seattle Children's Hospital
state: Washington
Study officials:
affiliation: Seattle Children's Hospital
name: Laura P Richardson, MD MPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Richardson LP, Zhou C, Gersh E, Spielvogle H, Taylor JA, McCarty CA. Effect of Electronic Screening With Personalized Feedback on Adolescent Health Risk Behaviors in a Primary Care Setting: A Randomized Clinical Trial. JAMA Netw Open. 2019 May 3;2(5):e193581. doi: 10.1001/jamanetworkopen.2019.3581.
Clinical trial NCT03746210: Non-Invasive Characterization of Focal Liver Lesions in Liver Cirrhosis
Official title: Non-Invasive Characterization of Focal Liver Lesions in Liver Cirrhosis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Liver Cirrhoses
Lead sponsor: University Hospital, Bonn
Sponsor class: OTHER
First posted: 2018-11-19
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study includes all adult patients in our institution with liver cirrhosis and diagnosis of focal liver lesions. Non-invasive charaterization (multiparametric ultrasound, sarcopenia assessment) and standard of care work up, treatment and follow up is applied to all patients.

Brief summary: This study aims to analyze non-invasive characterization focal liver lesions in patients with liver cirrhosis. The diagnostic accuracy and predictive value of non-invasive methods is studied.

Detailed description: This study aims to analyze non-invasive characterization focal liver lesions in patients with liver cirrhosis. The diagnostic accuracy and predictive value of non-invasive methods is studied.

Upon diagnosis multiparametric ultrasound imaging of the lesions as well as sarcopenia parameters are performed for characterization of the lesions. For primary endpoint the results are then analyzed with regard to diagnostic accuracy compared to gold standard (CT, MRI or histology). For secondary endpoint, predictive value of the non-invasive diagnostics are analyzed with regards to mortality and response to treatment.

All work up, treatment and follow up are applied in standard of care fashion.

Eligibility criteria: Inclusion Criteria:

* all patients with focal liver lesions and liver cirrhosis

Exclusion Criteria:

* no consent
* under 18 years

Primary outcomes:
measure: Diagnostic accuracy
timeFrame: 1 year
Secondary outcomes:
measure: Predictive Value
timeFrame: up to 5 years
Other outcomes:
Locations:
city: Bonn
country: Germany
facility: University Hospital Bonn
Study officials:
References:
Clinical trial NCT06750510: Digital Universal Parenting Program for Positive Parenting Behaviors
Official title: Digital Universal Parenting Program for Positive Parenting Behaviors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Parenting
Keywords: Parent-Training
Parenting
Lead sponsor: University of Turku
Sponsor class: OTHER
First posted: 2024-12-27
Enrollment: 1500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The goal of this study is to evaluate use and feasibility of digitally-delivered universal parenting program, which aims to promote positive parenting among guardians with 3 years-old children.

Detailed description: The study will use a single-arm study design.The participants will use the universal parenting program for 8-weeks.

The intervention is a digital parent training program which focuses on positive parenting and encouraging to develop parenting skills that strengthen the relationships and communication with their children. The topics includes for example reinforcing child´s positive behavior, reducing conflict situations and planning situations advanced, managing daily transitions, and being present to child. The program includes 5 themes with recommended length of 1 week each. Each theme includes theory material, videos, examples, video practices and exercises. The program is fully digital and provided in a dynamic, web-based format. SMS and email reminders will be sent regularly during the program.

Recruitment: All parents with a 3-year old child who is participating in annual health checkup in child health clinic are considered eligible to the study and are asked to participate if they fulfil inclusion criteria and do not meet the exclusion criteria.

Eligibility criteria: Inclusion Criteria:

* Guardians having a child aged 3 years participating to annual health checkup in child health clinic.
* At least one of the guardians is able to understand the languages that intervention is provided in

Exclusion Criteria:

* Inability to read Finnish, Swedish, or English, as these are the languages that the intervention is provided in.
* No internet access

Primary outcomes:
measure: Child´s affective reactivity
timeFrame: From baseline to 8-weeks follow-up
Secondary outcomes:
measure: Behaviour of the child
timeFrame: From baseline to 8-weeks follow-up
measure: Daily activities
timeFrame: From baseline up to 8-weeks
measure: Completion rates
timeFrame: From baseline up to 8-weeks
measure: Intervention satisfaction
timeFrame: 8-weeks follow-up
Other outcomes:
Locations:
city: Turku
country: Finland
facility: Kaisa Mishina
city: Turku
country: Finland
facility: Wellbeing service counties
Study officials:
affiliation: University of Turku
name: Andre Sourander, Professor, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06504810: Effect of Light Level on Stress, Anxiety, Psychological Well-being in Pregnant Women
Official title: Effect of Light Level on Stress, Anxiety, Psychological Well-being in Pregnant Women: Randomized Placebo-controlled Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Stress
Anxiety
Pregnant Women
Lead sponsor: Osmaniye Korkut Ata University
Sponsor class: OTHER
First posted: 2024-07-17
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: To determine the effect of light level on stress, anxiety and psychological well-being in pregnant women. This research was planned as a single-blind, randomized controlled experimental type study by comparing separate groups as experiment-placebo control. Data will be collected using the Introductory Information Form, Psychological Well-Being Scale, Perceived Stress Scale (ASÖ/PSÖ-14), and State-Trait Anxiety Inventory (STAI). The effect of two different amounts of light on pregnant women will be evaluated.

Detailed description: To determine the effect of light level on stress, anxiety and psychological well-being in pregnant women. This research was planned as a single-blind, randomized controlled experimental type study by comparing separate groups as experiment-placebo control. Data will be collected using the Introductory Information Form, Psychological Well-Being Scale, Perceived Stress Scale (ASÖ/PSÖ-14), and State-Trait Anxiety Inventory (STAI). The effect of two different amounts of light on pregnant women will be evaluated.

Eligibility criteria: Inclusion Criteria:

* Being 18 years or older,
* being in the last trimester of pregnancy,
* volunteering.

Exclusion Criteria:

* Having any problems that prevent you from communicating

Primary outcomes:
measure: stress
timeFrame: 1 day
Secondary outcomes:
measure: anxiety
timeFrame: 1 day
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01043510: The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin
Official title: A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of NN1250 at Steady State Conditions in Subjects With Type 2 Diabetes of Different Race and/or Ethnicity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Diabetes
Diabetes Mellitus, Type 2
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2010-01-06
Enrollment: 63
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the pharmacodynamic (effect) and pharmacokinetic (exposure of drug) properties of NN1250 (insulin degludec, IDeg) in subjects with type 2 diabetes of different race and/or ethnicity.


Eligibility criteria: Inclusion Criteria:

* Either - Black or African American not of Hispanic or Latino origin or - White of Hispanic or Latino origin or - White not of Hispanic or Latino origin
* Type 2 diabetes mellitus (as diagnosed clinically) for at least 12 months
* Treated with insulin for at least 3 months, alone or in combination with maximum 2 oral antidiabetic drugs (OADs)
* Body mass index maximum 40.0 kg/m\^2

Exclusion Criteria:

* Use of GLP-1 receptor agonists (exenatide, liraglutide), thiazolidinediones or dipeptidyl peptidase-4 (DPP-4) inhibitors within 3 months prior to screening
* History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction
* Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening

Primary outcomes:
measure: Area under the glucose infusion rate curve during one dosing interval at steady state
timeFrame: 0-24 hours (derived on treatment day 6)
Secondary outcomes:
measure: Area under the Insulin Degludec concentration-time curve during one dosing interval at steady state
timeFrame: 0-24 hours (derived on treatment day 6)
Other outcomes:
Locations:
city: Chula Vista
country: United States
facility: Novo Nordisk Investigational Site
state: California
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References:
citation: Hompesch M, Morrow L, Watkins E, Roepstorff C, Thomsen HF, Haahr H. Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus. Clin Ther. 2014 Apr 1;36(4):507-15. doi: 10.1016/j.clinthera.2013.12.014. Epub 2014 Feb 5.
citation: Heise T, Korsatko S, Nosek L, Coester HV, Deller S, Roepstorff C, Segel S, Kapur R, Haahr H, Hompesch M. Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action. J Diabetes. 2016 Jan;8(1):132-8. doi: 10.1111/1753-0407.12266. Epub 2015 Mar 24.
Clinical trial NCT04959110: Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT
Official title: Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Citrate Toxicity
Regional Citrate Anticoagulation
Liver Failure, Acute
Liver Failure, Acute on Chronic
Pharmacokinetic
Continuous Renal Replacement Therapy
Keywords: Regional citrate anticoagulation
Liver failure
Pharmacokinetics
CRRT
Cirrhosis
Lead sponsor: Chulalongkorn University
Sponsor class: OTHER
First posted: 2021-07-13
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Citrate has been proposed as anticoagulation of choice in continuous renal replacement therapy (CRRT). However, little is known about the pharmacokinetics (PKs) and metabolism of citrate in liver failure patients who require CRRT with regional citrate anticoagulation (RCA).

Detailed description: This study aimed to evaluate citrate PKs, metabolic complications, and clinical outcomes among critically ill acute liver failure (ALF) and acute on top chronic liver failure (ACLF) patients receiving CRRT.

Eligibility criteria: Inclusion Criteria:

* Critically ill ALF or ACLF adult patients with AKI
* aged ≥ 18 y old
* Currently receiving CRRT.

Exclusion Criteria:

* severe acidosis (pH \< 7.1) or severe alkalosis (pH \> 7.55)
* blood transfusion within 24 h prior to the study
* use of citrate-containing medications
* severe hypocalcemia (serum ionized calcium \< 0.8 mmol/L)
* use of heparin as anticoagulation

Primary outcomes:
measure: Citrate clearance
timeFrame: 4 hours
Secondary outcomes:
measure: Citrate accumulation
timeFrame: 4 hours
measure: Tmax
timeFrame: 2 hours
measure: Area under the time curve
timeFrame: 4 hours
measure: Change of systemic ionized calcium
timeFrame: 4 hours
measure: Change of ionized magnesium
timeFrame: 4 hours
measure: Change of bicarbonate
timeFrame: 4 hours
measure: Ratio of total calcium to systemic ionized calcium
timeFrame: 4 hours
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Chulalongkorn university
Study officials:
References:
Clinical trial NCT01016210: The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pregnancy Result Rape
Keywords: pregnancy
IVF
Lead sponsor: The Baruch Padeh Medical Center, Poriya
Sponsor class: OTHER_GOV
Collaborators: name: Ministry of Health, Israel
First posted: 2009-11-19
Enrollment: 60
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To explore whether recombinant LH (rLH) supplementation (Leuveris) to recombinant follicle stimulating hormone (rFSH) following GnRH antagonist treatment has an advantage in infertile women with advanced reproductive ageing undergoing IVF-ET.


Eligibility criteria: Inclusion Criteria:

* female candidate to IVF
* between 30-45 years old

Exclusion Criteria:

* not included for fertilization

Primary outcomes:
measure: Pregnancy rate
timeFrame: Starting February 2010
Secondary outcomes:
measure: Fertilization rate
timeFrame: Starting February 2010 till April 2013
Other outcomes:
Locations:
city: Tiberias
country: Israel
facility: Poriya hospital
Study officials:
References:
Clinical trial NCT03669510: Assessment of the Neurosensory Alteration After Inferior Alveolar Nerve Lateralization
Official title: Assessment of the Neurosensory Alteration With Computer Guided Inferior Alveolar Nerve Lateralization Versus Non Guided Classic Technique
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Implant Site Reaction
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-09-13
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: atrophic posterior mandible requiring nerve lateralization
Primary purpose: TREATMENT

Brief summary: : Assessment of the neurosensory alteration with computer guided inferior alveolar nerve lateralization versus non guided classic technique and measuring stability of implant after placement


Eligibility criteria: Inclusion Criteria:

* Adult patients with with atrophied posterior mandibular ridge
* both sexes
* NO intra oral soft and hard tissue pathology
* NO systematic that contraindicate implant placement

Exclusion Criteria:

* Presence pathological lesion
* Heavy smokers more than 20 cigarettes per day.
* patients with systemic disease that may affect normal healing

Primary outcomes:
measure: Assessment of the neurosensory alteration- sensation over time subjective(a scale 1-10)
timeFrame: 1 year
Secondary outcomes:
measure: Implant stability
timeFrame: At the placement and after exposure ( up to 6 months )
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dentistry, Cairo University
Study officials:
References:
Clinical trial NCT04220710: cfDNA in Diagnosis and Differential Diagnosis of Ovarian Endometriosis
Official title: Methylation of cfDNA in Diagnosis and Differential Diagnosis of Ovarian Endometriosis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Circulating Free DNA
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2020-01-07
Enrollment: 390
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. Marker selection group: patients with ovarian endometriosis, ovarian cancer and other benign ovarian tumors
2. Marker validation group: patients with ovarian cysts found through ultrasound ;

Brief summary: Methylation detection of circulating free DNA to identify markers for diagnosis and differential diagnosis of ovarian endometriosis.

Detailed description: Methylation detection of circulating free DNA and FFPF samples from patients with ovarian endometriosis, ovarian cancer and other benign ovarian cysts will be performed to select markers for ovarian endometriosis diagnosis. The markers will be validated in patients with ovarian cysts found by ultrasound. The diagnosis accuracy of the markers will be evaluated by comparing with the pathological diagnosis.

Eligibility criteria: 1. Marker selection group:

1. patients with ovarian endometriosis:

   Inclusion Criteria:
   1. pathologically diagnosed as ovarian endometriosis;
   2. surgery was performed in PUMCH

      Exclusion Criteria:

   a. combined with other gynecological benign and malignant tumors; b. clinically suspected malignant tumors; c. combined with other systemic malignancies or malignancies history; d. pregnant patients
2. patients with ovarian cancer:

Inclusion Criteria:

1. pathologically diagnosed as epithelial ovarian cancer;
2. surgery was performed in PUMCH

Exclusion Criteria:

1. combined with gynecological benign tumors and other malignant tumors;
2. combined with other systemic malignancies or malignancies history;
3. pregnant patients (3) patients with other benign ovarian tumors:

Inclusion Criteria:

1. pathologically diagnosed as benign ovarian tumors but not ovarian endometriosis;
2. surgery was performed in PUMCH

Exclusion Criteria:

a. combined with other gynecological benign and malignant tumors; b. clinically suspected malignant tumors; c. combined with other systemic malignancies or malignancies history; d. pregnant patients

2. Marker validation group:

Inclusion Criteria:

1. ovarian cysts found through ultrasound ;
2. surgery will be performed in PUMCH

Exclusion Criteria:

1. combined with other gynecological benign and malignant tumors;
2. clinically suspected malignant tumors;
3. combined with other systemic malignancies or malignancies history;
4. pregnant patients

Primary outcomes:
measure: The efficacy of cfDNA methylation in the diagnosis of ovarian endometriosis
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
Study officials:
References:
Clinical trial NCT00491010: Maximum Targeted Ablation of Atrial Flutter
Official title: Maximum Targeted Ablation of Atrial Flutter
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Atrial Flutter
Keywords: atrial flutter
ablation
voltage targeted
Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor class: OTHER
First posted: 2007-06-25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients undergoing atrial flutter ablation will be randomized to either the standard ablation approach or voltage targeted approach. Patients will be followed for one year to assess outcome of the ablation technique


Eligibility criteria: Inclusion Criteria:

* patients undergoing TV-IVC isthmus ablatin for atrial flutter

Exclusion Criteria:

* atypical atrial flutter
* \<18 years old any atrial surgery or pacemaker refusal to participate

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: Canada
facility: London Health Sciences Center
state: Ontario
Study officials:
affiliation: University of Western Ontario, London Health Sciences Center
name: Allan c Skanes, MD
role: PRINCIPAL_INVESTIGATOR
References: